Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/smll.200700580 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Site-Specific Molecular Engineering of Nanobody-Glucoside Conjugates for Enhanced Brain Tumor Targeting.
Bioconjug Chem
January 2025
Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Nanobodies play an increasingly prominent role in cancer imaging and therapy. However, their efficacy is often constrained by inadequate tumor penetration and rapid clearance from the bloodstream, particularly in brain tumors due to the intractable blood-brain barrier (BBB). Glycosylation is a favorable strategy for modulating the biological functions of nanobodies, including permeability and pharmacokinetics, but it also leads to heterogeneous glycan structures, which affect the targeting ability, stability, and quality of nanobodies.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.
Background: There is a strong link between tau and progression of Alzheimer's disease (AD), necessitating an understanding of tau spreading mechanisms. Prior research, predominantly in typical AD, suggested that tau propagates from epicenters (regions with earliest tau) to functionally connected regions. However, given the constrained spatial heterogeneity of tau in typical AD, validating this connectivity-based tau spreading model in AD variants with distinct tau deposition patterns is crucial.
View Article and Find Full Text PDFBackground: Different patterns of atrophy exist in the dementia stage of AD. However, little is known about the heterogeneity of atrophy patterns and the mechanisms that drive subsequent propagation of the disease in the preclinical stages.
Method: From the AMYPAD-PNHS cohort, we included a total of 1323 non-demented individuals, including 1094 amyloid-negative, and 229 amyloid-positive participants (Table 1).
Background: Recent advances in Alzheimer's Disease (AD) disease modifying therapies (DMTs) emphasize the need of an early, timely and accurate diagnosis to initiate treatment and improve patient outcomes. Clinicians must confirm amyloid pathology through cerebrospinal fluid (CSF) testing or amyloid positron emission tomography (PET) scan to qualify patients. As a result, the demand for confirmatory CSF or imaging biomarker testing is predicted to rise significantly.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Background: Experience-dependent cognitive plasticity can be induced by cognitive training well into the later decades of life. Although some prerequisites (education, intelligence) and constraints (age, genetic predisposition) on the extent of cognitive plasticity have been discussed, the impact of molecular age-related changes in the form of fibrillar amyloid pathology on plasticity remains to be investigated. Expanding our knowledge of potential contributors to the observed heterogeneity in intervention benefits may allow us to improve non-pharmaceutical interventions METHOD: Seventy-six healthy older adults (mean age = 68.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!